Review Note

Last Update: 10/29/2024 06:05 PM

Current Deck: Genes and Development::Week 4::LE031 TMAs-SLD

Published

Fields:

Text
TTP management via (x3)

{{c1::plasma exchange - removes anti-ADAMTS13 antibody to replace ADAMTS13 enzyme in blood which is not inhibited (**cornerstone treatment) or plasma transfusion 

immunosuppresion - steroids +/- rituximab (anti-CD20 inhibiting plasma cells which produces anti-ADAMTS13)

anti-vWF - caplacizumab so then platelets don't bind to vWF but then can have vWF disease of bleeding}}
Back Extra

Suggested Changes:

Deck Changes (Suggestion to move the Note to the following Deck):

Field Changes:

Tag Changes: